title: Risedronate therapy for prevention of hip fracture after stroke in elderly women.
abstract: BACKGROUND
  There is a high incidence of hip fractures in patients with hemiplegic stroke. Bone mineral density (BMD) is decreased in the hemiplegic side in patients after stroke, correlating with the degree of paralysis and of hypovitaminosis D.
  
  
  OBJECTIVE
  To evaluate the efficacy of risedronate in reducing the severity of osteoporosis and in decreasing the risk of hip fractures in elderly women following an acute stroke.
  
  
  METHODS
  This was a 12-month, randomized, double blind, placebo-controlled trial. In a prospective study of stroke patients, 187 patients received a daily dose of 2.5 mg risedronate for 12 months, and the remaining 187 received placebo. Incidence of hip fracture was compared between the two groups at the endpoint of the study.
  
  
  RESULTS
  Seven patients sustained hip fractures on the hemiplegic side in the placebo group, and one hip fracture occurred in the risedronate group (p = 0.0360; OR = 7.0). BMD increased by 1.5% and decreased by 4.9% in the risedronate group and placebo group (p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 53.4% in the risedronate group and increased by 35.8% in the placebo group.
  
  
  CONCLUSIONS
  Treatment with risedronate increases bone mineral density in elderly women following an acute stroke and prevents hip fractures.
authors.affiliation: Department of Neurology, Mitate Hospital, 3237 Yugeta, Tagawa 826-0041, Japan. y-sato@ktarn.or.jp
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Sato
authors.forename: Jun
authors.initials: J
authors.lastname: Iwamoto
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kanoko
authors.forename: Kei
authors.initials: K
authors.lastname: Satoh
mesh_terms: D000058:Accidental Falls / Q000706:statistics & numerical data; D000368:Aged; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006429:Hemiplegia / Q000150:complications*; D006620:Hip Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D010024:Osteoporosis / Q000517:prevention & control*; D010919:Placebos; D000068296:Risedronic Acid; D020521:Stroke / Q000150:complications*; D013995:Time; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D010919:Placebos; D000068296:Risedronic Acid; D012968:Etidronic Acid; D002118:Calcium